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Abstract
Background: A wealth of information on the functional roles of docosahexaenoic acid (DHA) and
arachidonic acid (ARA) from cellular, animal, and human studies is available. Yet, there remains a lack of
cohesion in policymaking for recommended dietary intakes of DHA and ARA in early life. This is
predominantly driven by inconsistent findings from a relatively small number of randomised clinical trials
(RCTs), which vary in design, methodology, and outcome measures, all of which were conducted in highincome countries. It is proposed that this selective evidence base may not fully represent the biological
importance of DHA and ARA during early and later life and the aim of this paper is to consider a more
inclusive and pragmatic approach to evidence assessment of DHA and ARA requirements in infants and
young children, which will allow policymaking to reflect the marked diversity of need worldwide.
Summary: Data from clinical RCTs is considered in the context of the extensive evidence from
experimental, animal and human observational studies. Although the RCT data shows evidence of
beneficial effects on visual function and in specific cognitive domains, early methodological approaches
do not reflect current thinking and this undermines the strength of evidence. An outline of a framework for
an inclusive and pragmatic approach to policy development on dietary DHA and ARA in early life is
described. Conclusion: High-quality RCTs that will determine long-term health outcomes in appropriate
realworld settings need to be undertaken. In the meantime, a collective pragmatic approach to evidence
assessment, may allow public health policymakers to make comprehensive reasoned judgements on the
merits, costs, and expediency of dietary DHA and ARA interventions.
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Abstract
Background: A wealth of information on the functional roles
of docosahexaenoic acid (DHA) and arachidonic acid (ARA)
from cellular, animal, and human studies is available. Yet,
there remains a lack of cohesion in policymaking for recommended dietary intakes of DHA and ARA in early life. This is
predominantly driven by inconsistent findings from a relatively small number of randomised clinical trials (RCTs),
which vary in design, methodology, and outcome measures,
all of which were conducted in high-income countries. It is
proposed that this selective evidence base may not fully represent the biological importance of DHA and ARA during
early and later life and the aim of this paper is to consider a
more inclusive and pragmatic approach to evidence assess-
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ment of DHA and ARA requirements in infants and young
children, which will allow policymaking to reflect the marked
diversity of need worldwide. Summary: Data from clinical
RCTs is considered in the context of the extensive evidence
from experimental, animal and human observational studies. Although the RCT data shows evidence of beneficial effects on visual function and in specific cognitive domains,
early methodological approaches do not reflect current
thinking and this undermines the strength of evidence. An
outline of a framework for an inclusive and pragmatic approach to policy development on dietary DHA and ARA in
early life is described. Conclusion: High-quality RCTs that will
determine long-term health outcomes in appropriate realworld settings need to be undertaken. In the meantime, a
collective pragmatic approach to evidence assessment, may
allow public health policymakers to make comprehensive
reasoned judgements on the merits, costs, and expediency
of dietary DHA and ARA interventions.
© 2018 S. Karger AG, Basel
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Introduction

Although the importance of fatty acids for human
health and well-being was initially recognised almost 90
years ago [1, 2], it is during the last 3 decades that there
has been considerable interest to understand the roles of
long chain polyunsaturated fatty acids (LCPUFAs) in infant growth and development [3–7]. The seminal work of
Manuela Martinez showing the rapid accretion of docosahexaenoic acid (DHA) and arachidonic acid (ARA) by
the infant brain during the first 1,000 days of life [8], was
the driver for many scientists, clinical researchers, nutritionists, developmental psychologists and epidemiologists to contribute to this important research domain.
Although there is now a wealth of information on the
functional roles of DHA and ARA from cellular, animal
and human studies, there remains a lack of cohesion in
policymaking on dietary intakes of DHA and ARA in
early life [9–11]. This predominantly relates to inconsistent findings from a small number of randomised clinical trials (RCTs). RCTs in infants born at term have been
the subject of 4 Cochrane systematic reviews [12–15].
These have each concluded that routine supplementation of full-term infant formula with LCPUFAs cannot
be recommended at this time [12–15]. Although the included RCTs have been rigorously reviewed, they vary
considerably in design, methodology and outcome measures, and were all conducted in high-income countries.
This selective evidence base may not fully represent the
biological importance of DHA and ARA during early
and later life, and consequently, current national and international policies may not adequately serve the needs
of all infants and children at a time of rapid growth and
development.
The aim of this paper is to examine the need for a more
inclusive and pragmatic approach to evidence assessment and policymaking, which will be more sensitive to
the DHA and ARA requirements of all children worldwide.

of four grades – High: confident that the true effect lies
close to the estimate of effect; Moderate: The true effect is
likely to be close to the estimate of effect but may be substantially different; Low: The true effect may be substantially different from the estimate of effect; and Very low:
The true effect is likely to be substantially different from
the estimated effect. Key elements of studies that may influence the strength of evidence include design and methods, dose-response associations, magnitude of effect, attrition rates and risk of bias that may decrease or increase
the observed effect and the estimated overall health gain
within the target population.
RCTs are generally viewed as high-grade evidence.
However, this can be altered if assessment demonstrates
that there are study limitations based on how the RCTs
were conducted and whether there are weaknesses in key
domains, for example, sample size and attrition [17–19].
In contrast, observational studies are generally assumed
to provide evidence of lower grade because of the higher
risk of bias attributable to lack of randomization and inability of investigators to control for known or unknown
confounding factors. However, the strength of the evidence base for observational studies may be raised by
methodological qualities such as large sample size and robust long-term data [17–19]. With these potential changes in strength of evidence, it is important that evidence
from all research sources is included in the assessment
process, and this is particularly relevant in public health
interventions.
Early Dietary Intake of DHA and ARA – What Is the
Evidence of Health Benefit from RCTs?

Cochrane reviews are undertaken using the Grading of
Recommendations Assessment, Development, and Evaluation (GRADE) system for rating quality of evidence
and grading strength of recommendations in systematic
reviews [16]. The GRADE approach results in an assessment of the quality of a body of evidence according to one

The objective of the Cochrane reviews was to assess
whether supplementation of formula milk with L
 CPUFAs
is both safe and beneficial for full-term infants, while focusing on effects on visual function, neurodevelopment
and physical growth [12–15].
In each of the reviews, only randomised and quasiRCTs were eligible for inclusion, and the studies selected
for review compared infant formula enriched with DHA
plus ARA or DHA alone, with infant formula that was
devoid of these fatty acids. The LCPUFA supplements
could be from any source including fish oil, egg triglycerides or algal oils. Eligibility for inclusion required the
following criteria – infants were ≥37 weeks of gestation
at birth; study formula was commenced within 2 weeks
after birth; study formula was the only source of milk
from the time of randomisation until at least 8 weeks of
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age; and a minimum of 3 months follow-up data on clinical outcomes of interest were available for analysis.
Types of outcome measures included visual acuity (measured using either Tellers cards or visual evoked potentials), neurodevelopmental outcomes (General Quotient,
Intelligent Quotient and other measures of cognitive
functions), and physical growth (weight, length and head
circumference).
The initial review in 2001 [12], included a final selection of 9 studies and in the most recent review [15], 31
studies were identified as potentially eligible, but following evaluation, only 15 were included. The final selection
of studies emerged from the GRADE system of rating
quality of evidence and grading strength of recommendations in systematic reviews [16]. The reasons for exclusion of 16 studies from the final analysis were – infants
also received breast milk, late introduction of intervention formula or the formula contained other nutrients of
interest, only laboratory outcomes were measured, study
was not blind or methods were not clear.
In the most recent review [15], it was noted that there
were no new cohorts since 2011, although there had been
further follow-up of the previous cohorts. Therefore, with
almost all the studies having been included in the previous reviews, it is not surprising that the conclusions in the
2017 review were in keeping with those of previous reviews. It was concluded that the majority of the RCTs did
not show beneficial effects of LCPUFA supplementation
on the neurodevelopmental outcomes of term infants,
that the beneficial effects on visual acuity had not been
consistently demonstrated, and finally, that routine supplementation of term infant milk formula with LCPUFA
cannot be recommended [15]. The reviewers did not express any concern regarding the safety of supplementation of infant formulas with DHA and ARA. However,
data on high-dose intervention is limited and Colombo
and colleagues have indicated that sustained attention
may be attenuated with DHA concentrations that are 3
times that of breast milk [20].
Although the studies had been rigorously assessed
from a design and methodology perspective, they are a
small disparate group of studies, demonstrating marked
variation in intervention source of fatty acids (egg phospholipid, algae, and fish oil), dose and duration of intervention, unknown levels of DHA and ARA intake from
complementary foods, differences in age at assessment,
and a diverse range of assessments (Table 1). With this
level of heterogeneity, it is difficult to draw an overriding
view on the health benefits of LCPUFAs in early life.
However, several studies did show evidence of beneficial
212
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effects on visual function, especially where there was a
combination of high dose and longer intervention duration, and in specific cognitive domains including problem solving and attention control (Table 1).
The heterogeneity in the design and methodology
used in the RCTs can be partly explained by the fact that
the studies were undertaken over a period lasting 2 decades and included the first RCTs of LCPUFAs undertaken in newborn infants. Understandably, the initial
designs and methods reflect a high level of caution and
are not representative of current thinking on dose and
duration of the intervention, and choice of assessments
[17]. None of the studies allowed for the effects of fatty
acid desaturase genotype on fatty acid status, and although current evidence indicates that the impact on
ARA levels, and to a lesser extent DHA, is limited compared to dietary intake, this variable should be considered in future studies [21]. It is also surprising that DHA
and ARA status of the participants was not routinely
measured in several of the included studies at the time
of recruitment and assessment to confirm differences in
status between intervention and control groups. Moreover, all the studies included in the review were undertaken in high-income countries, and on reflection it is
very likely that many of the participants were not DHA
or ARA deficient [18]. This would clearly attenuate the
effects of the intervention and importantly, would conceal potential beneficial effects in infants with low LCPUFA status.
It is important that researchers and policymakers distinguish between the appraisal of evidence and the process of making policy [19]. The comment by the Cochrane
reviewers that supplementation cannot be recommended
based on this RCT data is an appraisal of the evidence
based on their systematic review. However, public health
interventions are intended to promote or protect health
in communities or populations, and therefore policymaking has a broader perspective, which includes reducing
inequality and protecting the most vulnerable [19]. The
deficiencies in the reviewed RCTs that have been reported [17] should not only provide learning for researchers
and future RCTs but also provide a marker for policymakers as they determine which evidence will provide the
best policy on dietary LCPUFAs for vulnerable infants
and young children worldwide.
If new RCTs, which will address past methodological
issues and are conducted in appropriate real-world settings, are now commenced, definitive long-term data on
health outcomes will not be available for several years.
This presents a dilemma for public health policymakers –
Forsyth/Calder/Zotor/Amuna/Meyer/
Holub
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DHA (0.3%) and ARA (0.45%)

DHA (0.10%) and ARA (0.43%)

DHA (0.31%).

DHA (0.32%) and ARA (0.30%)

Carlson
et al. [72], 1996

Lapillonne et al.
[73], 2000

Lucas et al. [74],
1999

DHA (0.36%) and ARA (0.72%).

Birch
et al. [68], 1998

Bouwstra
et al. [71], 2005

LCPUFA content of the formula was
not clear

Ben
et al. [67], 2004

DHA (0.32%) and ARA (0.64%).
4 groups: control (0% DHA), 0.32%
DHA, 0.64% DHA, 0.96% DHA. For
Cochrane review, the 0.32% DHA
chosen as the intervention arm.

DHA (0.13%) and ARA (0.45%

Auestad
et al. [66], 2001

Birch
et al. [70], 2010

DHA (0.13%) and ARA (0.45%)
DHA alone (0.2%)

Auestad
et al. [65], 1997

DHA (0.36%) and ARA (0.72%)

DHA (0.3%) and ARA (0.44%)

Agostoni
et al. [64], 1995

Birch
et al. [69], 2005

Intervention

Researcher, year

309

24

39

6 months

4 months

1 year

2 months

up to 1 year of age

170

315

up to 52 weeks
of age

until 17 weeks
of age

up to 6 months
of age

4 months exclusive
and milk for
12 months

4 months exclusive
and milk for
12 months

4 months

Duration

103

79

121

404

134

60

Sample, n

Growth at 1, 2, 4, 6, 9 and 12 months.
Visual acuity at 2, 4, 6 and 12 months.
Fagan test of infant intelligence at 6 and
9 months, infant development at 6 and
12 months. Language development at 9
and 14 months. Parental reporting of
infant temperament at 6 and 12 Months

Visual function (VEP,
Teller Cards)
Neurodevelopment (BSID)
language (McArthur
communicative
development inventory)

Growth
Neurodevelopment (BSID)
gastrointestinal tolerance

Growth

Visual function (Teller cards)

Growth
Neurodevelopment (Hempel
and BSID)
Growth

Growth
Visual function (VEP)
Cognitive function,
attention control

Growth
Visual function (VEP)

Growth
Visual function (VEP)
Neurodevelopment (BSID)

Neurodevelopment at 18 months
Growth and gastrointestinal tolerance
at 6, 9 and 18 months

Weight, length and head circumference
at 2 and 4 months of age

Visual acuity at 2, 4, 6, 9, and
12 months *

Neurodevelopmental assessment
and growth, cardiovascular, cognitive
and behavioural assessments at 9 years

Visual acuity at 12 months.
Quality of attention, heart rate,
age-appropriate
standardised and specific cognitive
tests (18 months to 6 years every
6-monthly), growth until 6 years
of age, school readiness
and receptive vocabulary*

Growth, and visual acuity at 6, 17, 26,
39 and 52 weeks*

Growth and visual acuity at 6, 17, 26,
39 and 52 weeks. Infant development at
18 months*

Growth and neurodevelopmental
outcomes at 3 and 6 months of age

Growth at 1, 2, 4, 6, 9 and 12 months.
Visual acuity at 2, 4, 6, 9, 12 and
39 months. Neurodevelopment at
1 and 3 years. Language development
at 14 months and 3 years

Growth
Visual function (VEP, Teller Cards)
neurodevelopment
(BSID, Stanford-Binet IQ)
Language (McArthur
communicative
development inventory

Growth
Neurodevelopment

4, 12 and 24 months*

Age at assessment (* indicates beneficial effect in
vision or cognition)

Neurodevelopment
(Brunet-Lezine test)

Outcome measure

Table 1. Studies included in the Cochrane review 2017 [15] – listing researchers, intervention and duration, outcome measures and age at assessment

Infant cognition by a means-end
problem-solving test at 10 months.
Assessments of intelligence quotient
(IQ), attention control (Day-Night Test) and
speed of processing on Matching
Familiar Figures Test (MFFT)
in 6-year infants*
Cognitive function intelligence
4 months

DHA (0.2%) and ARA (0.4%).

DHA (0.15% to 0.25%) and ARA
(0.3% to 0.4%).

Morris
et al. [77], 2000

Willatts
et al. [78], 1998

109

DHA (0.34%) and ARA (0.34%)
DHA alone (0.34%)
Makrides et al. [76],
1999

72

Growth at 6 weeks, 3 months, 6 months and
1 year
12 weeks

Growth

Growth at 6, 16 and 34 weeks and at
1 and 2 years of age. Neurodevelopment
at 1 and 2 years
Growth, neurodevelopment (BSID),
Visual function (VEP)
4 months.
83

Vision at 16 and 30 weeks*
Visual function (VEP)
Neuro-development
up to 30 weeks of life
DHA (0.35%)
Makrides
et al. [75], 1995

32

Age at assessment (* indicates beneficial effect in
vision or cognition)
Outcome measure
Duration
Sample, n
Intervention
Researcher, year

Table 1. (continued)
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do they simply wait for RCT data to become available, or
do they endeavour to protect the interests of infants and
young children, especially those living in medium- and
low-income countries, by assessing the broader evidence
base and develop policies that are based on broad reasoned judgement?
What Do Experimental and Animal Studies Tell Us
about DHA and ARA in Early Life?

The n-3 LCPUFAs influence cellular membrane structure and function [3–7], and DHA is especially important
in the brain and retina, where it rapidly accumulates during the early years of life [8]. DHA is also the precursor of
potent lipid mediators called resolvins and protectins,
which play crucial roles in the prevention or treatment of
common chronic diseases that may lead to significant
morbidity and mortality. The n-6 LCPUFAs, particularly
ARA, are widely distributed throughout human cells and
tissues [6]. In addition to the central nervous system
where ARA plays an essential structural and functional
role, ARA is also a metabolic requirement for all cells as
a precursor for eicosanoids that modulate a variety of biological processes, particularly those relating to cerebral,
cardiovascular and immune function [6].
To assess the level of interest in experimental and animal research relating to DHA, an audit of all papers published on Medline over a 12-month period (January 1,
2016 to December 31, 2016) was undertaken [22]. The
search terms included (“docosahexaenoic acids” [MeSH
Terms] OR (“docosahexaenoic” [All Fields] AND “acids”
[All Fields]) OR “docosahexaenoic acids” [All Fields] OR
(“docosahexaenoic” [All Fields] AND “acid” [All Fields])
OR “docosahexaenoic acid” [All Fields]) AND (“animals”
[MeSH Terms:noexp] OR animal [All Fields]) AND 2016
[Date – Publication]. This search of a single research database identified 95 publications during the 12-month
search period, with 45 classified as primary scientific research, 20 human studies, observational and RCT studies,
27 reviews, and 3 studies that were considered not relevant.
During the 12-month period, there were 45 publications providing original scientific research on the role and
function of DHA with a focus on cellular metabolism or
effects on specific organ tissue, with studies relating to
brain and immune function being most prevalent. The research findings confirmed that DHA is metabolically relevant at all stages of the human life course, and that DHA
and its derivatives interact at multiple levels, including cell
Forsyth/Calder/Zotor/Amuna/Meyer/
Holub

membrane composition, metabolism, signal transduction
and amplification and gene expression. The relationship
of DHA to different biological systems throughout the human life course, underlines the importance of taking a
whole life perspective when considering the dietary needs
for DHA and other LCPUFAs in early life.
The number of papers relating LCPUFAs to immune
function reflects the increasing evidence that a chronic
low-grade inflammatory state is a pathological feature of
a wide range of chronic conditions, including the metabolic syndrome, nonalcoholic fatty liver disease, type 2
diabetes mellitus, and cardiovascular disease. There is
emerging information on novel mechanisms of action by
dietary fatty acids of different classes influencing inflammatory processes, some acting through proinflammatory
and others through anti-inflammatory or inflammationresolving mechanisms [23, 24]. Moreover, the balance between DHA and ARA is considered to have important
immunomodulatory roles during the postnatal period
when the immune system is rapidly developing; intervention studies have demonstrated improvement in many
markers of immune function in infants fed formula supplemented with ARA and DHA compared with unsupplemented formula, and this is associated with beneficial
health outcomes including reduction in the risk of developing allergic and atopic disease early in life [25].
The MEDLINE search identified 27 review articles, 18
referring to animal and human studies and 9 were exclusively related to human studies. A common theme was
that outcome measures were more consistent in animal
intervention studies, and translating this evidence to
health outcomes in humans has been challenging. This
discrepancy between animal and human data may partially relate to variance in methodology. In animal studies, the duration of dietary intervention is significantly
longer than in human intervention studies, when adjusted for the respective life expectances. The average age at
which mice attain puberty is 42 days, which is frequently
the duration of nutritional interventions in mice, including recent DHA studies [26]. There are no known human
RCTs where the dietary intervention was initiated at birth
and continued until puberty. The original rat studies by
George and Mildred Burr showed that it was several
months of total exclusion of fatty acids before the rats
showed obvious clinical signs of essential fatty acid deficiency [2]. It may be that longer duration of intervention
in humans will demonstrate later programming effects.
Data from the Cochrane review shows that in the majority of the RCTs involving DHA and ARA supplementation, the duration of supplementation was 4 months,

which is approximately 2–3 days in the life of a mouse
[27]. There are specific domains that may be sufficiently
sensitive to DHA and ARA and produce effects within a
relatively short period of intervention, but an expectation
that global neurodevelopment will be influenced by
4 months of supplementation is probably unrealistic.
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What Do Observational Studies Tell Us About DHA
and ARA in Early Life?

The MEDLINE search also identified 20 observational studies. Observational studies may represent a more
feasible study design for evaluating public health interventions than RCTs [19]. While RCTs (notably cluster
RCTs) can be designed to evaluate even complex public
health programs, often they are not feasible because of
logistic or resource constraints. Even a carefully planned
study such as the Promotion of Breastfeeding Intervention Trial, which was described as the largest RCT of human lactation, and was led by 2 international research
teams from Canada and England, and conducted in a
country that is structured and organised, the cluster randomisation model was undermined by the unexpected
withdrawal of 3 clusters. This led to an imbalance in the
randomisation model and the analysis needed to include
adjustments for potential confounding variables, as is
done in observational studies [28]. With the scientific,
logistic, and financial pressures in conducting long-term
RCTs, it may be constructive to pragmatically balance
the need for a robust study design with the need for evidence that is inclusive and relevant to the needs of the
target population. Under these circumstances, an observational study may not only be informative but also perceived as being low risk, cost effective and scientifically
appropriate.
There have been several interesting observational
studies that investigated the relationships between dietary or circulating n-3 LCPUFAs and all-cause mortality, and these have recently been assessed by a systematic review and meta-analysis that included 11 prospective observational studies [29]. The studies included
371,965 participants from general populations and considered 31,185 death events. From this analysis, the
dose-response indicated that for each 0.3 g/day increment in n-3 LCPUFA intake, there was an associated
6% lower risk of all-cause mortality and for each 1%
increment in the proportions of circulating DHA and
EPA in total fatty acids in blood there was an associated
21 and 20% decreased risk of all-cause mortality respec215

tively. Moderate to high heterogeneity was observed
across the analysis, but the authors concluded that the
findings suggest that both dietary and circulating
LCPUFA are inversely associated with all-cause

mortality [29].
Hibbeln et al. [30] utilized data from the Food and
Agriculture Organisation (FAOSTAT) [35] to measure
n-3 LCPUFA dietary intake in 38 predominantly developed countries and related that data to age-adjusted
mortality due to cardiovascular disease, coronary heart
disease, and stroke. They determined that the greatest
protection was provided by a total n-3 LCPUFA dietary
intake of 750 mg/day, which most closely correlated with
the dietary intake of the Japanese population. They commented that Japan is a modern industrialized society
with a large population and well-documented rates of illnesses and nutrient intakes. Low rates of cardiovascular
disease have been consistently reported in Japan, despite
high rates of smoking and hypertension [34]. Moreover,
when the Japanese move to the United States and consume a diet low in n-3 LCPUFAs, the risk of cardiovascular disease increases, suggesting that the protective effect is not genetic [31].
In a multinational study, published mathematics test
scores from the Program for International Student Assessment of the Organization for Economic Cooperation and Development, which is a single test that is administered in a consistent way to 15-year-old students
in 59 countries, were related to national data on maternal milk DHA levels in 28 high- and medium-income
countries from both the Northern and Southern Hemispheres [32]. The findings showed a strong correlation
between breast milk DHA levels and cognitive performance in the mathematics test with the observed association remaining highly significant after controlling for
national wealth, investment in education and macronutrient intake.
Although observational studies tend to raise further
research questions, multinational observation studies
that, for example, relate early life dietary intake of DHA
(and other LCPUFAs) to later life health outcomes, merit consideration by public health policymakers.
What Is the Best Evidence for Public Health
Policymakers?

To increase the value of health care services, many
countries have established programs or independent
agencies that inform health care decision-making
216
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through systematic reviews of healthcare interventions,
for example, the National Institute for Health and Clinical Excellence in the United Kingdom [33] and in the
United States, the Agency for Healthcare Research and
Quality created the Effective Health Care (EHC) Program in 2005 [34]. A key element of the EHC program,
is the Comparative Effectiveness Review, the aim of
which is to determine how the relative benefits and
harms of a range of options compare, rather than to answer a narrow question on whether a single therapy is
safe and effective [35–38]. As noted in the Cochrane
reviews of LCPUFAs, it is not unusual for the number
of RCTs that are available to provide direct comparisons
to be relatively small, and there is then a risk that the
body of evidence is insufficient to draw robust conclusions about comparative benefits and harms. It is also
noted that in the 2017 review [15], there were no new
cohorts since 2011. Under these circumstances, there is
a need to seek a more wide-ranging opinion from the
research literature, including evidence from experimental studies, placebo-controlled trials, and observational
studies.
In the consideration of observational studies by Comparative Effectiveness Reviews, it is emphasised that systematic reviewers should answer 2 specific questions –
first, are there gaps in the RCT evidence to satisfactorily
address the review questions that are under consideration? And second, will observational studies provide valid and useful information to address these key questions?
[35, 38]. It is clearly stated that there is no a priori reason
to exclude observational studies from research questions
on health benefit, but they should be evaluated on the
same criteria used to evaluate the inclusion of RCT data,
namely, whether the observational study results address
the key question and whether the observational data are
likely to be valid.
It is also noted that in relation to applicability of evidence, and the relevance to the target population and
setting, observational studies may be particularly insightful [35–38], and therefore, they may be particularly relevant in public health interventions that focus
on promoting or protecting health at community and
national levels. The public health considerations of a
specific health issue within a population will generally
include – the perceived magnitude and importance of
the problem, the potential effectiveness and harms of an
intervention, the feasibility of its implementation, and
its political and public acceptability [19]. Decisionmaking around dietary LCPUFAs in early life is an important public health issue, and for informed policy deForsyth/Calder/Zotor/Amuna/Meyer/
Holub

cision-making, a broader examination of the
literature may allow the process to progress from research evidence to policy implementation in a timelier
manner.

The World Health Organisation (WHO) recommends
that mothers worldwide exclusively breastfeed infants for
the child’s first 6 months to achieve optimal growth, development and health. Thereafter, they should be given
nutritious complementary foods and continue breastfeeding up to the age of 2 years or beyond [39]. It is recognised that additional nutrient dense complementary
foods (liquid and solid) are required following the exclusive breastfeeding period to prevent under-nutrition and
stunting in the childhood population [40].
Human milk is a complex dynamic bioactive fluid
which, in addition to containing essential nutrients for
normal growth and development, has several compositional components that make it unique. Unlike infant formula, which is standardised within a very narrow range
of composition, human milk composition is dynamic,
and varies during a feeding, diurnally, during the period
of lactation, and between mothers and populations [41].
A potent example of human milk uniqueness is the consistent presence of significant quantities of DHA and
ARA [42, 43] and this contrasts with the trace amounts
that may be found in cow’s milk, goat milk, soya milk and
rice milk [44]. The level of availability of DHA and ARA
in human milk, as opposed to that in other animal and
plant milks, is highly indicative of their essentiality for
human infants. Moreover, there are documented mechanisms that actively transport DHA and ARA through the
placenta from the mother to the fetus during pregnancy
[45] and for DHA and ARA to be released from maternal
lipid stores and transported to the breast during lactation
[46]. These evolutionary mechanisms enhance the delivery of DHA and ARA to the fetus during the prenatal period and to the infant post birth. Endogenous synthesis of
DHA and ARA is limited in infants [47] and therefore the
infant is dependent upon dietary sources of both DHA
and ARA.
Amounts of DHA and ARA in human milk tend to
vary by maternal diet and nutritional status [42, 43].
Based on data from 65 studies of milk from 2,474 women, the mean concentration of ARA (% fatty acids by
weight) was 0.47% (range 0.24–1.0%) and the mean con-

centration of DHA was 0.32% (range 0.06–1.4%). The
levels of DHA were particularly low in populations with
the greatest poverty – 0.06% DHA in Pakistan, Northern
Sudan, and 0.10% DHA in Southern Sudan [42]. Applying the WHO recommendation on exclusive breast feeding for 6 months, it is estimated that at 6 months, infants
will be receiving approximately 171 mg/day of ARA and
111 mg/day of DHA, based on a breast milk intake of 854
mL/day [48] and the reported mean concentrations of
DHA and ARA in human milk [42]. An infant receiving
a formula without supplemented DHA and ARA will
clearly have zero consumption from milk feeds during
this time and it has been shown that these infants not
only have lower blood levels of DHA [49], but the accretion of both DHA and ARA in the brain is significantly
lower in infants fed a formula that is devoid of these fatty acids [49, 50].
Complementary foods tend to have low concentrations of DHA and ARA and this is evident in both highand low-income countries [51–54]. In low-income
countries, it is common practice for weaning infants to
receive the food from the family bowl, which is most
commonly of plant origin and will have low ARA and
DHA content. In a recent publication, the dietary intake
of ARA and DHA at the population level was strongly
related to the economic status of the country [55]. The
analysis was based on food consumption data originally
collected by the Food and Agriculture Organisation
(FAO) [56] and by applying food composition tables,
the per capita dietary intakes of DHA and ARA were
estimated for 175 countries worldwide, with 47 classified as developed and 128 as developing. This analysis
demonstrated that per capita intakes of both fatty acids
varied significantly in relation to the gross national income of the country, with low-income countries having
intakes of DHA and ARA, which were only 20–25% of
that of high income countries. The 28 countries in the
lowest income category had per capita median DHA
and ARA intakes of 47 and 43 mg/day, respectively, and
this group represents a total population of nearly 740
million people. There was considerable regional variation with lowest intakes for both ARA and DHA being
in Sub-Saharan Africa and Southern, Western and Central Asia [55].
Estimates were also made of DHA and ARA intakes
during the age period of 6–36 months [57]. This analysis
estimated intakes of DHA and ARA from breast milk and
complementary foods using published data on median
duration of breast feeding, mean concentration of DHA
and ARA in breast milk, and mean intakes of breast milk.
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The dietary intakes of DHA and ARA in infants and
young children aged 6–36 months from 76 developing
countries (17 upper middle income, 34 lower middle income, and 25 low income) were 48.8 and 63.7 mg/day
respectively. The contribution of DHA and ARA intake
from complementary foods was directly related to the
gross national income of the country and the intakes of
DHA and ARA from complementary foods following the
discontinuation of breast feeding for the 76 countries
were 14.6 and 17.9 mg/day, respectively, and in the lowest income countries, intakes fell to 9.6 and 8.9 mg/day
respectively. The DHA and ARA intake from complementary foods was exceptionally low in the poorest resource countries, especially Nepal (DHA 0.7 mg/day;
ARA 1.1 mg/day), Ethiopia (DHA 1.1 mg/day; ARA 3.8
mg/day), and Rwanda DHA 1.8 mg/day; ARA 1.7 mg/
day) [57, 58].
This evidence, which was based on data originally
collected by the FAO, shows that many millions of infants and young children, especially the most vulnerable
living in low-income countries have a dietary intake of
DHA and ARA, which is significantly low compared to
current international recommendations. The FAO has
provided specific recommendations on dietary intakes
of DHA in infants and young children stating that from
0–6 months the daily requirement is 0.1–0.18%E of
DHA (equivalent to a mean of 102 mg/day); for 6–24
months, DHA requirement is 10–12 mg/kg bodyweight
(equivalent to 70–120 mg/day); for 2–4 years, DHA and
EPA 100–150 mg/day, with DHA and EPA increasing to
200–250 mg/day at age 6–10 years [10]. In 2013, the
European Food Safety Authority recommended an adequate intake of 100 mg/day DHA for older infants
(>6 months of age) and young children below the age of
24 months [59] and in 2014, European Food Safety Authority determined adequate nutrient intakes of LCPUFA from birth to the age of 24 months as 100 mg DHA/
day [9]. There are few explicit dietary recommendations
for ARA. However, an expert advisory group recommended that during the first months of life, infants
should receive 140 mg ARA/day [60]. A study in Belgium noted that in children 2.5–3 years of age, the DHA
intake was 45 mg/day and for ARA 17 mg/day, indicating that intake in this high-income country, was significantly below recommended levels [61]. Codex Alimentarius has identified DHA as an optional ingredient for
infant formulas and stated that if DHA is added to infant
formula, a guidance upper level should be 0.5% fatty acids, the ARA content should reach at least the same concentration as DHA; and the content of eicosapentaenoic
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acid that can occur in sources of LCPUFA, should not
exceed the content of DHA. National authorities may
deviate from the above conditions, as appropriate for the
nutritional needs [62]
The consequences of an inadequate intake of DHA
and ARA, and other key nutrients, are preventable. Researchers, healthcare workers, policymakers, and other
key actors need to consider the level of evidence required and decide what actions are appropriate for this
strength of evidence. The transferability of the evidence
into practice requires a weighing of multiple factors
such as the perceived magnitude and importance of the
problem, the potential effectiveness and harms of the
intervention, the feasibility of its implementation, its
political acceptability and the public demand for action
[19]. Although different interest groups may advocate
for competing recommendations based on the same evidence, it is critical that the dietary needs of the most
vulnerable infants are at the center of the discussion.
Progress will require a pragmatic approach, which may
become incremental, as future evidence becomes available. To reach an agreement on the balance between the
level of evidence and the measures required to address
the need, a framework consisting of key questions is proposed (Appendix).
Conclusions

Relating early life nutritional interventions to later life
health outcomes is always going to be challenging and all
research methods will have their limitations. There is a
real concern that inconsistency in RCTs of LCPUFA supplementation may be misinterpreted as indicating that
low dietary intake of DHA and ARA will be of no consequence to even the most vulnerable infants. Recent evidence indicates that a high proportion of the global childhood population may be at risk of LCPUFA deficiency in
early life [55, 57, 58].
It is important that the body of research available to policymakers reflects the socio-economic, cultural, dietetic
and genetic diversity of the populations being considered,
and that studies are inclusive and focus on those individuals and communities that are at greatest risk. In some settings, observational studies may represent the most feasible
and appropriate study designs for identifying at-risk populations and evaluating public health interventions.
With the first 1,000 days of life being a critical period
for normal growth and development, a key objective of an
incremental pragmatic approach to dietary DHA and
Forsyth/Calder/Zotor/Amuna/Meyer/
Holub

ARA in early life should be to establish an LCPUFA safety net for the most vulnerable infants worldwide. This can
be achieved by ensuring that levels of DHA and ARA in
infant formulas, follow-on formulas, and complementary
foods reflect published data on median levels of DHA and
ARA in breast milk.

Appendix
An Evaluation Framework for a Pragmatic Approach to Policy
Issues on Dietary DHA and ARA in Early Life
Why Is a Pragmatic Approach Being Considered?
A key principle of the EHC Program is that the questions that
are being addressed in reviews must be answered at a time when
decision makers need the information. The slow and unpredictable translation of research into practice has been linked to the assertion that the evidence base should be developed through traditional explanatory models and efficacy designs rather than be the
product of more pragmatic methodologies. Pragmatic models
such as those adopted by the EHC have evolved to identify benefits
and potential harm and to address practical issues that may provide momentum to the translation of research evidence to effective
implementation.
The distinction between the appraisal of research evidence and
the process of making policy is particularly important when considering what question(s) needs to be answered. From a research
perspective, the Cochrane review asked the question – Is DHA and
ARA supplementation of infant formulas beneficial and safe? A
public health policy question that views the issue from a population perspective could be – Should measures be taken to ensure
that at-risk infants and young children receive food sources that
will adequately complement their current low DHA (and ARA)
intakes? Clearly these questions are not mutually exclusive, if the
evidence from the first question indicated that there was no evidence of benefit and that the intervention was potentially harmful,
public health policymakers would reject their policy proposal.
However, as there is some evidence of benefit, there is no evidence
of harm, and there is non-RCT evidence indicating that inadequate
dietary intake of DHA and ARA in early and late life has potentially serious health consequences, the pragmatic public health
question has merit and justifies consideration.

a largely irreversible outcome of inadequate nutrition and repeated bouts of infection, during the first 1,000 days of a child’s life.
Inadequate provision of complementary foods, especially animal
foods, is a key factor in the development of acute malnutrition,
stunting and mortality. With low intakes of marine and animal
food, (and therefore low intakes of DHA and ARA), being associated with stunting, DHA and ARA food sources or supplements
need to be made available to infants and young children who are
at greatest risk [55, 57, 58]. If current trends continue, projections
indicate that 127 million children under the age of 5 years will be
stunted in 2025 [63]. WHO global recommendations on complementary feeding encourage consumption of healthy, diversified
diets, including high-quality, nutrient-rich, animal source food
during the period 6–23 months [40].
What Is the Evidence to Support a Pragmatic Dietary DHA
and ARA Intervention in Early Life?
There is lack of consistency in the evidence from RCTs and
this is related to weaknesses in design and methodologies, especially in early studies. Although there is evidence of benefit in vision and some specific aspects of cognition, there are learning
points for new-quality RCTs that need to be conducted in appropriate settings. While the outcome of these studies is awaited (and
this may be in several years), it is important to consider other
supporting evidence that is emerging from experimental, animal,
and observational data, including the immunomodulatory roles
of DHA and ARA in early life, when the immune system is rapidly developing. A pragmatic approach that is based on the totality of evidence can begin to constructively address the inadequate
dietary intake of DHA and ARA in the at-risk infant and child
population.

What Is the Driver for this Public Health Policy Question?
The main complementary food source for DHA is oily fish and
for ARA meat, poultry and eggs. Any child who has a diet that is low
in marine and animal foods will become deficient in these fatty acids.
Recent published evidence indicates that dietary intakes of DHA and
ARA in infants and young children aged 6–36 months are significantly lower than current recommendations, especially in low income countries [55, 57, 58]. From a policy perspective, the issue
meets the principal objectives of public health policies which are to
improve population health, avoid harm and reduce health inequality.

What Is the Intervention, How Will It Be Implemented, and
How Will Outcomes Be Measured?
The main objective of the intervention will be to increase the
availability of DHA and ARA food sources and relevant nutritional products for at-risk populations, and this should be part of
a wider initiative to promote effective coordination and collaboration through integrated, multisectoral action, supported by effective governance of food systems at all levels, and facilitated by
high-level political support. Maintaining the momentum of
growth in agricultural productivity will be crucial in the coming
decades with a stronger focus on nutrient-dense foods such as
fruits, vegetables, legumes and animal-source foods. These actions need to be supported by nutrition, health, and education
institutions, industry and other professional and voluntary organisations. Food sources for DHA and ARA, and specific nutritional products are currently widely available in high-income populations and this availability now needs to extend to countries in
greatest need. Inherent within the pragmatic approach is a flexibility that will allow opportunities for local teams and communities to have local ownership of the policy and investigation of the
effects of implementation, and be able to make refinements to the
process, based on intermittent evaluation and real-time and realworld data.

What Is the Magnitude of the Issue?
The WHO has stated that childhood stunting is one of the most
significant impediments to human development globally, affecting
approximately 162 million children under the age of 5 years. It is

Is This a Cost-Effective Solution?
Malnutrition imposes unacceptably high costs on society in human and economic terms. Recent research showed that investing
US$1.2 billion annually in micronutrient supplements, food forti-
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fication and biofortification of staple crops for 5 years would generate annual benefits of US$15.3 billion, a benefit-to-cost ratio of
almost 13–1, and this would result in better health, fewer deaths
and increased future earnings [6]. Child and maternal malnutrition is the largest nutrition health burden in the world.
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